

Special Issue

Immunotherapy: New Prospective in the Treatment of Ovarian Cancer

Message from the Guest Editors

Ovarian cancer still remains the major unresolved problem of gynaecologic oncologists in terms of efficient treatment.

Due to the great importance that immunological fitness has in the clinical outcome, large efforts have been made to develop new immunotherapeutic strategies to be administered alone or in combination with standard therapies. In addition to the development of novel immunotherapy approaches, several questions that could impact the long-term results of any immunological intervention need further investigation. Timing of immunological treatment and integration with the several currently adopted therapeutic strategies and drug administration approaches (administration schedule, intravenous vs intraperitoneal vs intranodal, dosage, etc.) represent critical issues that need to be resolved.

This Special Issue is focused on novel therapeutic strategies (immunotherapy alone or combined with standard therapies or other agents), innovative administration schedule, new immune targets, novel ideas and approaches to further improve the therapeutic efficacy of immunotherapy.

Guest Editors

Dr. Chiara Napoletano

Department of Experimental Medicine, "Sapienza" University of Rome, Viale Regina Elena 324, 00161 Rome, Italy

Prof. Dr. Filippo Bellati

Department of Gynecology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy

Deadline for manuscript submissions

closed (31 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/47218

Cancers

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

cancers@mdpi.com

mdpi.com/journal/

[cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)